Get the Stockscreener App
1.09
8.40%
-0.10
Pre-market:
1.10
0.01
+0.92%
Heron Therapeutics Inc stock is traded at $1.09, with a volume of 2.68M.
It is down -8.40% in the last 24 hours and down -23.24% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$1.19
Open:
$1.21
24h Volume:
2.68M
Relative Volume:
1.62
Market Cap:
$199.87M
Revenue:
$137.74M
Net Income/Loss:
$-27.97M
P/E Ratio:
-6.8125
EPS:
-0.16
Net Cash Flow:
$-9.61M
1W Performance:
-8.40%
1M Performance:
-23.24%
6M Performance:
-22.14%
1Y Performance:
-38.42%
1-Day Range:
$1.07
$1.215
1-Week Range:
$1.07
$1.2399
52-Week Range:
$0.9999
$2.68
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
1.09 | 218.20M | 137.74M | -27.97M | -9.61M | -0.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
487.43 | 122.19B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.19 | 83.21B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
840.28 | 51.13B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.85 | 43.68B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
369.00 | 41.01B | 4.98B | 69.60M | 525.67M | 0.5198 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-09-25 | Initiated | H.C. Wainwright | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
Aug Sectors: Whats Heron Therapeutics Incs historical returnWeekly Profit Recap & Technical Pattern Based Signals - baoquankhu1.vn
Heron Therapeutics Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Heron Therapeutics, Inc. (HRTX) Stock Analysis: Exploring A Potential Upside Of 258.13% - DirectorsTalk Interviews
Heron Therapeutics, Inc. $HRTX Shares Acquired by JW Asset Management LLC - MarketBeat
Heron Therapeutics (HRTX) Expected to Announce Earnings on Thursday - MarketBeat
Aug EndMonth: What are JOFF Fintech Acquisition Corp Debt Equity Composite Unitss growth leversMarket Trend Report & Verified Entry Point Detection - baoquankhu1.vn
Heron: Near The Bottom Of A Trading Range Despite Positives (NASDAQ:HRTX) - Seeking Alpha
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 - The Manila Times
Should I set a stop loss on Heron Therapeutics Inc.Dollar Strength & Entry Point Confirmation Signals - mfd.ru
Can Heron Therapeutics Inc. expand into new marketsWeekly Risk Report & Breakout Confirmation Trade Signals - mfd.ru
How does Heron Therapeutics Inc. compare to its peersJuly 2025 Weekly Recap & Community Consensus Trade Alerts - mfd.ru
How strong is Heron Therapeutics Inc. (AXD2) stock earnings growthJuly 2025 WrapUp & Safe Capital Growth Tips - mfd.ru
How resilient is Heron Therapeutics Inc. stock in market downturnsJuly 2025 Rallies & Free Accurate Trade Setup Notifications - mfd.ru
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Here's Why Heron Therapeutics (NASDAQ:HRTX) Has A Meaningful Debt Burden - simplywall.st
Is Heron Therapeutics Inc. impacted by rising rates2025 Market Outlook & Weekly Hot Stock Watchlists - mfd.ru
New York State Common Retirement Fund Buys 816,671 Shares of Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron Therapeutics, Inc. (HRTX): Investor Outlook Reveals Potential 240.91% Upside - DirectorsTalk Interviews
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast - Defense World
Heron Therapeutics (NASDAQ:HRTX) Shares Pass Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Heron Therapeutics (HRTX) director reports 53,960-share RSU grant and large fund stake - Stock Titan
Heron Therapeutics, Inc. (HRTX) Stock Analysis: Exploring A 238% Upside Potential - DirectorsTalk Interviews
Investment Report: What are the risks of holding Heron Therapeutics Inc2025 Trade Ideas & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
What are the risks of holding Heron Therapeutics IncTrade Entry Report & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Heron Therapeutics (NASDAQ:HRTX) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Stock Passes Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Breakeven Is Near for Heron Therapeutics, Inc. (NASDAQ:HRTX) - Yahoo Finance
Aug Technicals: Is Heron Therapeutics Inc impacted by rising ratesQuarterly Investment Review & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Whale Trades: Will Heron Therapeutics Inc stock benefit from M A2025 Breakouts & Breakdowns & Proven Capital Preservation Tips - baoquankhu1.vn
Will Heron Therapeutics Inc. stock gain from strong economyMarket Sentiment Summary & Weekly High Potential Stock Alerts - Bollywood Helpline
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Quarterly Trades: Can Heron Therapeutics Inc expand into new marketsStock Surge & Verified Momentum Stock Ideas - baoquankhu1.vn
VIX Spike: Is Heron Therapeutics Inc affected by consumer sentimentEarnings Growth Report & Fast Entry Momentum Alerts - baoquankhu1.vn
Aug Drivers: Is Heron Therapeutics Inc stock vulnerable to regulatory risksEntry Point & Smart Money Movement Alerts - Bộ Nội Vụ
Heron rises as preliminary revenue figures exceed estimates - MSN
Returns Recap: Does Heron Therapeutics Inc stock trade at a discount to peers - moha.gov.vn
Great week for Heron Therapeutics, Inc. (NASDAQ:HRTX) institutional investors after losing 10% over the previous year - simplywall.st
Heron Therapeutics’ Q4 Earnings Beat Forecasts, Boosted by Acute Care Success - timothysykes.com
HC Wainwright Reaffirms Buy Rating for Heron Therapeutics (NASDAQ:HRTX) - Defense World
Heron Therapeutics’ Revenue Soars Beyond Expectations in Q4 2025 - StocksToTrade
Heron Therapeutics Revenue Exceeds Estimates with Strong Acute Care Performance - StocksToTrade
Heron Therapeutics Surpasses Revenue Expectations with Significant Growth - timothysykes.com
Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M - Yahoo Finance
How supply chain issues affect Heron Therapeutics Inc. stockMarket Sentiment Review & Real-Time Stock Movement Alerts - Улправда
How Heron Therapeutics Inc. stock reacts to global recession fears2025 Price Momentum & Daily Profit Focused Stock Screening - Улправда
Can Heron Therapeutics Inc. stock surprise with earnings upsideCEO Change & Real-Time Buy Signal Alerts - Улправда
Heron Therapeutics Expands Strategic Vision Amid Market Fluctuations - StocksToTrade
Heron Therapeutics Reports Strong Preliminary Q4 2025 Revenue - TipRanks
HRTX: HC Wainwright & Co. Reiterates Buy Rating with $6 Price Ta - GuruFocus
Heron Therapeutics' (HRTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Heron Therapeutics stock soars after strong Q4 revenue growth By Investing.com - Investing.com Canada
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.20%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):